Page last updated: 2024-10-30

lansoprazole and Cystic Fibrosis

lansoprazole has been researched along with Cystic Fibrosis in 5 studies

Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.

Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

Research Excerpts

ExcerptRelevanceReference
" In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function."9.09Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001)
" In this prospective open study of 14 children with cystic fibrosis (CF), we evaluated the effect of 1 year adjuvant therapy with lansoprazole, a proton pump inhibitor (PPI), on growth, fecal fat loss, body composition and lung function."5.09Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis. ( Donckerwolcke, R; Forget, PP; Hendriks, JJ; Kester, AD; Wouters, EF, 2001)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chung, WJ1
Goeckeler-Fried, JL1
Havasi, V1
Chiang, A1
Rowe, SM1
Plyler, ZE1
Hong, JS1
Mazur, M1
Piazza, GA1
Keeton, AB1
White, EL1
Rasmussen, L1
Weissman, AM1
Denny, RA1
Brodsky, JL1
Sorscher, EJ1
Tran, TM1
Van den Neucker, A1
Hendriks, JJ2
Forget, P1
Forget, PP4
Kester, AD1
Donckerwolcke, R1
Wouters, EF1
Hendriks, HJ2
van Kreel, B1
ter Heide, H1
Heijmans, H1
Menheere, PP1
Spaapen, LJ1
Bakker, JA1

Trials

1 trial available for lansoprazole and Cystic Fibrosis

ArticleYear
Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis.
    Pediatric pulmonology, 2001, Volume: 31, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adipose Tissue; Adolescent; Body Composition; Body Height;

2001

Other Studies

4 other studies available for lansoprazole and Cystic Fibrosis

ArticleYear
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu

2016
Effects of a proton-pump inhibitor in cystic fibrosis.
    Acta paediatrica (Oslo, Norway : 1992), 1998, Volume: 87, Issue:5

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anthropometry; Celiac Disease; Child; Ch

1998
Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients.
    Journal of pediatric gastroenterology and nutrition, 2001, Volume: 33, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Infective Agents; Biomarkers; Child; Child

2001
Are children with cystic fibrosis who are treated with a proton-pump inhibitor at risk for vitamin B(12) deficiency?
    Journal of pediatric gastroenterology and nutrition, 2001, Volume: 33, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Case-Control Studies; Child; Child, Preschool;

2001